Acquisition by Magrath George of 90294 shares of Opus Genetics, at 1.0102 subject to Rule 16b-3
IRD Stock | 0.99 0.16 19.28% |
About 72 percent of all Opus Genetics,'s shareholders are curious in acquiring. The analysis of overall sentiment of trading Opus Genetics, stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Opus Genetics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Opus Genetics, stock news signals to limit their universe of possible portfolio assets.
Opus |
Filed transaction by Opus Genetics, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Opus Genetics,'s cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Opus Genetics,'s relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Opus Genetics, Fundamental Analysis
We analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Opus Genetics, is rated second overall in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Opus Genetics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Opus Genetics, stock to make a market-neutral strategy. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics with similar companies.
Peers
Opus Genetics, Related Equities
IRD | Opus Genetics, | 19.28 | ||||
DWTX | Dogwood Therapeutics, | 0.86 | ||||
TLX | Telix Pharmaceuticals | 3.18 |
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |